Trial · NCT01273896
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
NCT01273896, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2015-11-20
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer. Trials, record NCT01273896. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01273896
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
- NCT number
- NCT01273896
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 22 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Breast Cancer
- Interventions
- STA-9090
- First posted
- 2011-01-11
- Last updated
- 2015-11-20
- Results first posted
- 2015-11-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate | Radiological imaging studies to evaluate tumor status will be repeated during the rest week (Days 22 to 28) of every third cycle | To determine the overall response rate using RECIST v 1.1 criteria, defined as PR +CR.using RECIST v 1.1 criteria, defined as Partial response + complete response |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate | Radiological imaging studies to evaluate tumor status will be repeated during the rest week (Days 22 to 28) of every third cycle | participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate | STA-9090 | 20 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | STA-9090 | 22 | |
| Overall Study | COMPLETED | STA-9090 | 22 | |
| Overall Study | NOT COMPLETED | STA-9090 | 0 |
Source ClinicalTrials.gov
Adverse events35
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT | Investigations | STA-9090 | 2 | 22 | 5 |
| other | AST, SGOT | Investigations | STA-9090 | 4 | 22 | 9 |
| other | Alkaline phosphatase | Investigations | STA-9090 | 4 | 22 | 8 |
| other | Amylase | Investigations | STA-9090 | 2 | 22 | 7 |
| other | Bilirubin (hyperbilirubinemia) | Investigations | STA-9090 | 3 | 22 | 4 |
| other | CPK (creatine phosphokinase) | Investigations | STA-9090 | 1 | 22 | 3 |
| other | Creatinine | Investigations | STA-9090 | 1 | 22 | 1 |
| other | Diarrhea | Gastrointestinal disorders | STA-9090 | 4 | 22 | 6 |
| other | Dry mouth/salivary gland (xerostomia) | Gastrointestinal disorders | STA-9090 | 1 | 22 | 1 |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | STA-9090 | 2 | 22 | 2 |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | STA-9090 | ||
| Total, other adverse events | STA-9090 | 20 | 22 |
| Total, serious adverse events | STA-9090 | 6 | 22 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01273896
GET https://conductscience.org/api/trials/v1/NCT01273896/events?page=2